Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Bailey

Day

. Thiazolidinediones today. Br J Diabetes Vasc Dis 2001;1:7-13.

Day

. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16:179-92.

Bailey

. The rise and fall of troglitazone. Diabet Med. 2000;17: 414-5.

Nissen

Wolski

Topol

. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2005;294:2581-2586.

Conlon

. Goodbye glitazars? Br J Diabetes Vasc Dis 2006;6: 135-137.

Nissen

Wolski

. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007; 356:2457-2471

Goldberg

Kendall

Deeg

. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care. 2005;28:1547-54.

Lincoff

Wolski

Nicholls

Nissen

. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials. JAMA. 2007;298:1180-88.

Nissen

. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224741.pdf

10.

Graham

Ouellet-Hellstrom

MaCurdy

. Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone. JAMA. 2010;304: 411-18.

11.

Lewis

Ferrara

PengHedderson

. FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Diabetes Care. 2011;34: 916-22.

12.

Mamtani

Haynes

Bilker

. Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study. ASCO 2012; Abstract 1503.

13.

Habib

Havstad

Wells

Divine

Pladevall

Williams

. Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2010; 95:592-600.

14.

Tseng

. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012;35:278-80.

15.

Dormuth

Carney

Carleton

. Thiazolidinediones and Fractures in Men and Women. Arch Intern Med 2009;169: 1395-1402.

16.

Zinman

Haffner

Herman

. ADOPT Study Group. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. J Clin Endocrinol Metab 2010;95:134.

17.

van Lierop

A H

Hamdy

N A T

van der Meer

R W

. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 2012;166:711-16.

18.

Staels

. The clinical significance of PPAR α and γ agonism. Br J Diabetes Vasc Dis 2002;2:suppl 1, S28-31.

19.

McDonald

Cavey

Cole

. Identification of a Mitochondrial Target of Thiazolidinediones (mTOT). Diabetes 2012; 61:suppl 1, Abstract 1096-P.

20.

Poster session presented at: Clinical Diabetes and Therapeutics. American Diabetes Association 72nd Annual Meeting; 2012 Jun 8-12; Philadelphia, PA; Abstract 1096-P.

21.

Bricker

Taylor

Schell

. A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans. Science: 337:6090;96-100.

22.

Herzig

Raemy

Montessuit

. Identification and Functional Expression of the Mitochondrial Pyruvate Carrier. Science 337:6090; 93-96.

23.

Colca

VanderLugt

Adams

. Clinical proof of concept with a prototype mTOT modulating insulin sensitizer. Diabetes 2012; 61:suppl 1, Abstract 966-P.

PPAR γ Agonists and the Future for Insulin Sensitizers

Abstract

Get full access to this article

References